华东医药(000963.SZ)：注射用HDM2005临床试验申请获得批准

智通财经网2025-05-06

华东医药(000963.SZ)发布公告，2025年5月6日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(通知书编号：2025LP01259)，由中美华东申报的注射用HDM2005临床试验申请获得批准。据悉，注射用HDM2005是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类生物新药，是一款靶向受体酪氨酸激酶样...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533506338?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-06 17:21","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2533506338","market":"sg","top_or_hot":-1,"title":"华东医药(000963.SZ)：注射用HDM2005临床试验申请获得批准","media":"智通财经网","content":"<div>\n<p>华东医药(000963.SZ)发布公告，2025年5月6日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(通知书编号：2025LP01259)，由中美华东申报的注射用HDM2005临床试验申请获得批准。据悉，注射用HDM2005是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类生物新药，是一款靶向受体酪氨酸激酶样...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrkux0607733.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华东医药(000963.SZ)：注射用HDM2005临床试验申请获得批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华东医药(000963.SZ)：注射用HDM2005临床试验申请获得批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-06 17:21 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrkux0607733.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>华东医药(000963.SZ)发布公告，2025年5月6日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(通知书编号：2025LP01259)，由中美华东申报的注射用HDM2005临床试验申请获得批准。据悉，注射用HDM2005是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类生物新药，是一款靶向受体酪氨酸激酶样...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrkux0607733.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrkux0607733.shtml","article_id":"2533506338","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533506338","pubTimestamp":1746523260,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"华东医药发布公告，2025年5月6日，公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，由中美华东申报的注射用HDM2005临床试验申请获得批准。注射用HDM2005在中国和美国的临床试验于2024年6月分别获得NMPA和美国食品药品监督管理局批准，适应症为晚期恶性肿瘤。2025年2月，HDM2005的套细胞淋巴瘤适应症获得美国FDA孤儿药资格认定。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0183":"MSCI概念","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK1141":"生命科学工具和服务","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0209":"零售","BK1583":"高瓴概念","BK1576":"医药外包概念","BK0188":"融资融券","000963":"华东医药","03347":"泰格医药","BK0132":"高送转概念"},"translate_title":"Huadong Medicine (000963. SZ): HDM2005 clinical trial application for injection approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"000963":1},"content_text":"华东医药(000963.SZ)发布公告，2025年5月6日，公司全资子公司杭州中美华东制药有限公司(“中美华东”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(通知书编号：2025LP01259)，由中美华东申报的注射用HDM2005临床试验申请获得批准。据悉，注射用HDM2005是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类生物新药，是一款靶向受体酪氨酸激酶样孤儿受体1(ROR1)的抗体偶联药物(ADC)。注射用HDM2005在中国和美国的临床试验于2024年6月分别获得NMPA和美国食品药品监督管理局(以下简称“美国FDA”)批准，适应症为晚期恶性肿瘤。中国I期临床已完成前四个剂量爬坡，均未发生DLT(剂量限制性毒性)，目前在第五个剂量爬坡给药阶段，同步进入第四个剂量组的扩展阶段。2025年2月，HDM2005的套细胞淋巴瘤(MCL)适应症获得美国FDA孤儿药资格认定。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533506338","isCrawlerRequest":true}